Filing Flows › Cytek Biosciences (CTKB) › Q3 2025
Cytek Biosciences (CTKB) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Cytek Biosciences (CTKB) reported revenue of $52.3M for the third quarter 2025 (Q3 2025), +2% from a year earlier and +15% from the quarter before. Operating margin was -17.6%, net loss $5.5M (10.5% of revenue).
Cytek Biosciences, Q3 2025: revenue $52.3M (+2% year over year), operating margin -17.6%, net loss $5.5M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $52.3M | +15% | +2% |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$5.5M | — | — |
| Operating cash flow | −$3.9M | -3709% | — |
What changed
Revenue was $52.3M in Q3 2025, up 2% year over year and up 15% from the previous quarter. Product was the largest line at 73% of revenue. Service added $2.2M year over year (up 19%), 280% of the total change. Product declined 4%.
Gross margin was 52.7%, down 3.6 points from a year earlier. Operating costs exceeded revenue by $9.2M, an operating margin of -17.6%. Operating expenses grew 10% against revenue growth of 2%. The fastest-growing cost line was General & admin (+47%). The quarter ended with a net loss of $5.5M, narrower than the previous quarter's $5.6M loss.
Operating cash flow was −$3.9M. Non-cash charges added back $1.9M of depreciation and amortization and $5.6M of share-based compensation. Working capital and other items used $6.0M. Capital expenditures of $657K exceeded it, leaving free cash flow of −$4.6M.
Questions
What was Cytek Biosciences' revenue in the third quarter 2025?
Cytek Biosciences (CTKB) reported revenue of $52.3M for the third quarter 2025 (Q3 2025), +2% from a year earlier and +15% from the quarter before.
Was Cytek Biosciences profitable in the third quarter 2025?
Operating loss was $9.2M (-17.6% of revenue) and net loss $5.5M.
Source: Cytek Biosciences 10-Q on SEC EDGAR.